ArticleInfectious diseases and therapy2025
Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe effectiveness of AZD7442 (tixagevimab/cilgavimab) against COVID-19 hospitalizations was determined at 3 and 6 months among immunocompromised individuals in Israel during different variant circulations.
methodsThis was a retrospective cohort study using data from Clalit Health Services in Israel. Immunocompromised individuals eligible to receive AZD7442 300 mg between 15 February and 11 December 2022 were identified. Immunocompromised individuals receiving AZD7442 300 mg as pre-exposure prophylaxis (PrEP) were propensity score (PS)-matched 1:1 to unexposed individuals using a "rolling cohort" approach. Calendar time Cox proportional hazards regression models were performed with adjustment for post-matched unbalanced covariates to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).
resultsOverall, 2444 AZD7442-exposed immunocompromised individuals were PS-matched to unexposed individuals. In the matched population, up to 6 months of follow-up, AZD7442 300 mg presented an unadjusted HR (without adjustment for the unbalanced covariates) of 0.68 (95% CI 0.43-1.08) and covariate-adjusted HR of 0.64 (95% CI 0.40-1.03) against COVID-19 hospitalization. Covariate-adjusted instantaneous hazards plots showed that the effectiveness of AZD7442 300 mg waned from Day 90. Up to 3 months of follow-up, the unadjusted HR was 0.43 (95% CI 0.21-0.91) for AZD7442 300 mg against COVID-19 hospitalization in the matched population; there were insufficient events to allow covariate-adjusted analysis.
conclusionOur results suggest that AZD7442 300 mg reduced COVID-19 hospitalizations among immunocompromised individuals; however, the findings are limited by a lack of sufficient events to produce conclusive results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.